As part of Grupo NC, one of the largest conglomerates in Brazil, Galenika is a company that operates on the global market. Its focus is on further expansion to international markets and the 2023 plan includes further expansion on the EU market, with the goal of launching products in Croatia and Slovenia
Galenika has a new Executive Director for Sales and Marketing, who will take advantage of his enviable experience to additionally expand operations and position new products. Here he reveals for our readers what he will do to ensure Galenika achieves its global goals.
Over the course of the 26 years of your career to date, you have amassed great experience and achieved a series of successes at major national and multinational pharmaceutical companies. How useful is that experience to you today?
Working in various segments of the pharma industry led to me facing many challenges, but also opportunities.
I have solid experience in implementing and achieving results in areas of management, commercial, demand and marketing, with strategic performance and support in restructuring within multicultural business environments. My experience in implementing strategic and innovative initiatives allowed me to redesign assertive plans many times, and accordingly to market trends to adapt the existing business model. This is something that I plan to implement at Galenika in order for it to achieve its global goals.
Galenika operates successfully on 17 international markets of Europe, the Middle East and Africa. Will you take advantage of your enviable experience to additionally expand its operations and position new products?
As part of Grupo NC, one of the largest conglomerates in Brazil, Galenika is a company that operates on the global market. Our focus is further expansion on international markets. In 2022, through Galenika International ltd., our subsidiary in Hungary, we launched Galenika products for the EU market for the first time.
In the non-prescription drugs and food-supplement segment, Galenika has 14 leading brands that are among the top three in their respective categories in Serbia, including 8 that are number 1
We plan further expansion on the EU market in 2023, with the goal of launching products in Croatia and Slovenia, while we are also planning, among other things, to extend our footprint to new markets in the coming years. These plans may sound like a challenge, but I strongly believe that my international experience of the European and Latin American markets, including market global strategy localisation, will contribute to achieving this goal.
You and your team are working full steam ahead on the implementation of ambitious plans for 2023 and the coming years. Could you share some details of those plans with us and our readers?
To illustrate Galenika’s way of thinking – I am proud to say that in the non-prescription drugs and food-supplement segment, Galenika has 14 leading brands that are among the top three in their respective categories in Serbia, including 8 that are number 1!
However, our business aspirations do not stop there. In that regard, we created a new portfolio structure and process to monitor and track innovative products that form part of our new action plan. This also encompasses new marketing and sales tools in order to reach our 2023 goals. The focus will be on new launches of strategic brands, both in Serbia and the markets of the region.
Despite you having only been based in Serbia for just seven months, we’re sure that you’ve managed to familiarise yourself with our culture. What do you like in Serbia?
I have a friend in Brazil, an ophthalmologist, whose is of Serbian origin. He mentioned to me that Serbia is the “European Brazil”. The way people celebrate and the way they welcome foreigners is very similar to Brazilian people…Having been in Serbia for seven months, I can truly confirm the veracity of all his words and I’m very happy to have an opportunity to live and work in this country.
